Merck to Takeover Chromatography Business of JSR Life Sciences

Business Deal Merck to Takeover Chromatography Business of JSR Life Sciences

2025-10-16 Source: Press release Merck 2 min Reading Time

Related Vendors

Merck KGaA

DÜPERTHAL Sicherheitstechnik GmbH & Co. KG

Turck_Your_Global_Automation_Partner.jpg ()

TURCK GmbH

ProMinent GmbH

Merck has entered into a definitive agreement to acquire the chromatography business of JSR Life Sciences. With this move, Merck has plans to expand its downstream processing portfolio.

Merck has recently announced the signing of a definitive agreement to acquire the chromatography business of JSR Life Sciences. (Source: Pixabay) — Merck has recently announced the signing of a definitive agreement to acquire the chromatography business of JSR Life Sciences.
(Source: Pixabay)

Darmstadt/Germany – Merck has recently announced the signing of a definitive agreement to acquire the chromatography business of JSR Life Sciences, a leader in contract development and manufacturing, preclinical and translational clinical research, and bioprocessing solutions. The acquisition will expand Merck’s downstream processing portfolio with advanced Protein A chromatography capabilities, supporting more efficient and scalable production of biopharmaceutical therapies, including monoclonal antibodies. The transaction is expected to close by the end of the second quarter of 2026.

“This acquisition will strengthen our position in the bioprocessing market and underscores our commitment to long-term investment in monoclonal antibody production technologies,” said Sebastián Arana, Head of Process Solutions, Life Science business of Merck. “By combining JSR’s Protein A expertise with our portfolio, we can further enable customers to advance the speed, efficiency, and reliability of antibody therapy production.”

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

Protein A chromatography plays a critical role in the purification of monoclonal antibodies and therapeutic proteins, which are used for treating cancers, autoimmune diseases, and infectious conditions. This specialized purification process is key to achieving high purity and enhanced drug safety, while also improving manufacturing speed and reliability. Ultimately, that means helping patients gain faster access to critical therapies.

Based in Belgium, the chromatography business of JSR Life Sciences has more than 50 employees and supplies chromatography solutions to pharmaceutical and biotech manufacturers worldwide. The company is known for its high-performing Amsphere A3 and Amsphere A+ Protein A resins, which offer superior purification performance and process robustness for a wide range of monoclonal antibodies.

"This acquisition positions our innovative Amsphere Protein A technologies for even greater global impact under Merck's renowned platform—enabling more customers worldwide to accelerate therapies to market with enhanced speed and confidence”, said Tim Lowery, President of JSR Life Sciences.

(ID:50593974)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.